


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
 Substitute for form 1449/PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/669,819
Filing Date	September 23, 2003
First Named Inventor	Lyn Howard Jones
Art Unit	To Be Announced
Examiner Name	To Be Announced
Attorney Docket Number	PC25377A

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	DOCUMENT NUMBER Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
YD	AA	60/432,859	12/11/2002	Pfizer Inc.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
YD	AB	WO91/11172	08/08/1991	The University of Kansas		
	AC	WO94/02518	02/03/1994	The University of Kansas		
	AD	WO98/55148	12/10/1998	Janssen Pharmaceutica N.V.		
	AE	W002/04424	01/17/2002	Pfizer Limited		
	AF	WO 02/30907	04/18/2002	F. Hoffmann-La Roche AG		
	AG	WO02/34745	05/02/2002	Anormed Inc.		
✓?	AH	UK 0223232.0	10/07/2002	Pfizer Limited		

EXAMINER:

T.A. Solola

DATE CONSIDERED:

11-10-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

Complete if Known

Application Number	10/669,819
Filing Date	September 23, 2003
First Named Inventor	Lyn Howard Jones
Art Unit	1626
Examiner Name	To Be Announced
Attorney Docket Number	PC25377A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

NOV 10 2003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
70/	AI	BERGE, et. al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> , 1977, 1-19, Vol. 66, No. 1.	
✓	AJ	BIGHLEY, et. al., "Salt Forms of Drugs and Absorption," <i>Encyclopedia of Pharmaceutical Technology</i> , Marcel Dekker Inc., 1996, 453-497, Vol 13, New York.	
✓	AK	BUNDGAARD, et. al., <i>Design of Prodrugs</i> , 1985, Chapter 1, Elsevier Science Publishers, Amsterdam, New York, Oxford.	
*	AL	GAREY, et. al., "Structure and Mechanisms," <i>Advanced Organic Chemistry</i> , 3 rd Edition, Plenum Press, New York and London. <i>No publication date</i>	
70/	AM	FERRES, ET. AL., "Pro-Drugs of β -Lactam Antibiotics," <i>Drugs of Today</i> , 1983, 499-538, Vol. 19, No. 9.	
✓	AN	GENIN, et. al., "Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus the Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives," <i>Journal of Medicinal Chemistry</i> , 2000, 1034-1040, Vol. 43, No. 5	
✓	AO	GREENE, et. al., <i>Protecting Groups in Organic Synthesis</i> , 1991, Second Edition, John Wiley & Sons, New York, Chichester, Brisbane, Toronto, Singapore.	
✓	AP	KATRITZKY, et. al., "The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds," <i>Comprehensive Heterocyclic Chemistry</i> , 1984, Vol. 1-11, Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt	
**	AQ	Topics in Chemistry, Chapter 31, 306-316, (Not Available) <i>Not submitted</i>	

EXAMINER:

T.A. Sobola

DATE CONSIDERED:

11-10-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.